中老年男性常见病：FDA批准良性前列腺增生新疗法ENTADFI

Benign prostatic hyperplasia (BPH) is one of the common diseases in middle-aged and elderly men. As the global population ages, its incidence is increasing. Medically speaking, benign prostatic hyperplasia is not a fatal disease. Its main clinical manifestations are frequent urination, urgency, difficulty urinating or nocturia, etc. Most men with sub-healthy bodies will have it. Although this is not a very serious disease, it still requires attention.

On December 13, 2021, Veru announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by benign prostatic hyperplasia (BPH).

Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer, said, "The approval of ENTADFI, a new therapy for the treatment of BPH, is a major milestone for Veru and an important step in growing revenue for our commercial health segment. We use these revenues to invest in and advance our late clinical-stage oncology pipeline portfolio, as well as our global Phase 3 COVID-19 Clinical studies. We are seeking additional partners and expect to begin commercialization in early 2022. Approximately billions of dollars are spent on the treatment of BPH each year, with more than 45 million patients in the United States alone, and this market is expected to continue to grow as the male population ages.”

References:

https://www.globenewswire.com/news-release/2021/12/13/2350788/11676/en/Veru-Announces-FDA-Approval-of-ENTADFI-a-New-Treatment-for-Benign-Prostatic-Hyperplasia.html